Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B.

In this episode, we discuss:
 • Why Gilgamesh is building psychedelic medicines the way large pharma would
 • The thesis behind short-acting psychedelics and why long-duration trips are impractical for real-world psychiatry
 • How Gilgamesh designs molecules backwards from clinical needs
 • Effective approaches to the challenges of trial designs for psychedelics 
 • What AbbVie’s deal and Spravato’s trajectory mean for psychedelics
 • How psychedelic medicines could reshape mental health

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias and Greg
Produced by Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg speaks with three leaders in mental health philanthropy: Alyson Nieman from Mindful Philanthropy, Sabrina Gracias from Ortus Foundation, and Christena Huntsman Durham from Huntsman Mental Health Foundation, each offering a distinct perspective on how funding decisions get made and where the biggest gaps remain.

In this episode we discuss:

• Trends in mental health philanthropy, and the 10-year challenge: how the field moves from roughly $2B to $35B in annual funding.
• Funding the clinic of the future: a $150M philanthropic gift behind the Huntsman Mental Health Institute’s crisis care center
• Youth mental health: how the Ortus Foundation is addressing regional gaps in the US Intermountain West

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg interviews Rick Perry, the former Governor of Texas and former U.S. Secretary of Energy and leading advocate for ibogaine, live at the Real Summit.

In this episode, we discuss:

• How a former Texas governor moved from strict opposition to drugs to becoming a leading advocate for ibogaine after firsthand experience and veteran outcomes.
• Ibogaine’s impact on PTSD, opioid addiction, and traumatic brain injury, including Stanford-linked brain imaging data showing functional and structural improvement.
• How veterans are the proving ground that enabled Texas to commit $50M in public funding for ibogaine clinical trials.
• Why ibogaine requires intensive medical supervision and why rigorous trials are essential for legitimacy and scale.
• A vision where ibogaine reshapes addiction treatment, veteran care, and eventually criminal justice and homelessness policy.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS.

In this episode, we discuss:

• Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuro
• How brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBB
• How new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders 
• Why delivery route of shuttles enable IV or subcutaneous dosing instead of invasive intrathecal injections
• How early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effects
• How the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platforms

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery. 

In this episode, we discuss: 

• How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogue
• Why healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies with human-in-the-loop to enhance quality of care
• Why human oversight is essential and how AI can augment complex clinical work instead of replacing it
• The competitive advantage from workflows, data, and trust via purpose built AI systems
• The path toward precision psychiatry, where continuous, language-based interactions can generate rich behavioral data to inform diagnostics, treatment, and drug discovery

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Matias interviews Rob Malenka.

In this episode, we discuss:

• Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneous
• The bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatry
• How breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropy
• How success depends on mission-driven, ethical people who align science, capital, and patient impact.
• The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Brendon Boot of Skin2Neuron. Brendon is a neurologist at Harvard and Mayo Clinic with prior experience as Medical Director at Biogen overseeing their Phase 1b Alzheimer’s trials.

In this episode, we discuss:

• How skin-derived cells can be turned into neurons to repair the brain.
• Why replacing lost neurons may succeed where drugs have failed in Alzheimer’s.
• What makes autologous (self-derived) cell therapy safer and more effective.
• How testing in dogs brought stronger proof than traditional mouse models.
• Why this approach could shift Alzheimer’s treatment from slowing decline to restoring memory.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Natalie Yivgi-Ohana of Minovia. Natalie is a life science entrepreneur with twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. 

In this episode, we discuss:

• How mitochondria impacts health by not just regulating energy, but also hormones, cell survival, and overall cellular function
• Why mitochondrial dysfunction is a root cause of many conditions, from rare genetic disorders to aging and mental health issues.
• What mitochondrial therapy does by restoring function and improving cellular health
• What makes mitochondrial therapies distinct from gene therapies
• How to scale mitochondrial therapies for clinical adoption

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Matias and Greg interview Ying-Hui Fu, PhD, is a Professor of Neurology at UCSF and a world leader in the genetics of sleep. Her lab has discovered the first-known genes behind “natural short sleepers”. Her work bridges human genetics and neuroscience to uncover how to modulate sleep for brain health, aging, and neurodegenerative diseases.

In this episode, we discuss:

• How some people thrive on 4–6 hours of sleep with rare genetic mutations
• Why sleep efficiency is more important than total hours slept
• What short sleeper genes reveal about preventing Alzheimer’s and autism
• Why current sleep research tools miss deeper brain activity patterns
• What’s next in sleep science with potential therapies

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Matias and Greg interview Justin Mares, co-founder of TrueMed and Kettle & Fire on current US healthcare and how startups have the opportunity to change the system.

In this episode, we discuss:

• How the US system profits from chronic illness
• Fixing the food system, environmental toxins, pharma incentives & more
• Opportunities for founders building in brain and body health.
• Contrarian ideas Justin is investing in today

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Caitlin Ner & Nico V. Rey 

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Matias and Greg interview Dr. Nir Grossman, one of the world’s leading researchers in neurotechnology. Nir is a lecturer in the Department of Brain Sciences at Imperial College London and a founding fellow of the UK Dementia Research Institute. 

In this episode, we discuss:

• What is temporal interference (TI), a non-invasive stimulation method
• A comparison of TI with deep brain stimulation (DBS)
• How physics plays a crucial role in neuroscience innovation
• Translating TI academic research to clinical use
• TI’s role in treating Alzheimer’s, epilepsy, depression, and traumatic brain injury

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis,  Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank